Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Benzylaminopurine SCHEMBL29772173 | 0.80 | LMNA (0.62) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| 6-Benzylaminopurine SCHEMBL28824679 | 0.80 | LMNA (0.62) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| 6-Benzylaminopurine SCHEMBL37357 | 0.80 | LMNA (0.62) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| SCHEMBL10649362 | 0.80 | LMNA (0.67) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| SCHEMBL4920550 | 0.78 | AURKA (0.48) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| 6-Benzylaminopurine SCHEMBL218732 | 0.78 | LMNA (0.61) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| 6-Benzylaminopurine SCHEMBL8378677 | 0.78 | LMNA (0.61) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| SCHEMBL15950904 | 0.78 | LMNA (0.47) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| 6-Benzylaminopurine SCHEMBL11477799 | 0.78 | LMNA (0.61) | LMNACYP1A2CYP2D6TSHRCDK2 | |
| SCHEMBL722909 | 0.77 | EGFR (0.52) | LMNACYP1A2CYP2D6TSHRCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116975-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | ADORA3, ADORA2A, ADORA2B | LMNA 1763/4885CYP1A2 825/4885CYP2D6 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.